Patients with focal segmental glomerulosclerosis (FSGS) achieved some degree of proteinuria remission more often and more ...

A post-hoc analysis of the DUPLEX trial shows significantly greater improvements in proteinuria-related outcomes vs irbesartan for tough-to-treat FSGS.

BOSTON — Adults recently diagnosed with immunoglobulin A nephropathy who were assigned sparsentan as first-line therapy experienced rapid and sustained reductions in proteinuria, according to ...

The late-breaking oral presentation will feature new analyses from the Phase 3 DUPLEX Study of FILSPARI® (sparsentan) in focal segmental glomerulosclerosis (FSGS), showing that partial and ...

Travere Therapeutics and partner CSL Vifor could be weeks away from EU approval of sparsentan for IgA nephropathy, after getting a positive opinion on the drug from the EMA’s human medicines ...

Travere Therapeutics has submitted a supplemental New Drug Application (sNDA) to the FDA for FILSPARI (sparsentan) as a priority review for the treatment of focal segmental glomerulosclerosis ...

The two-year results from the study were published in the New England Journal of Medicine and showed that sparsentan delivered clinically meaningful benefit at 108 weeks with significant ...

SAN DIEGO, March 31, 2025--(BUSINESS WIRE)--Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the Company will present three abstracts, including one late-breaking oral presentation ...